Microfluidics in High-Throughput Drug Screening: Organ-on-a-Chip and C. elegans-Based Innovations

Author:

Yoon Sunhee1ORCID,Kilicarslan You Dilara1ORCID,Jeong Uiechan2,Lee Mina1,Kim Eunhye1,Jeon Tae-Joon134ORCID,Kim Sun Min124ORCID

Affiliation:

1. Department of Biological Sciences and Bioengineering, Inha University, Incheon 22212, Republic of Korea

2. Department of Mechanical Engineering, Inha University, Incheon 22212, Republic of Korea

3. Department of Biological Engineering, Inha University, Incheon 22212, Republic of Korea

4. Biohybrid Systems Research Center (BSRC), Inha University, Incheon 22212, Republic of Korea

Abstract

The development of therapeutic interventions for diseases necessitates a crucial step known as drug screening, wherein potential substances with medicinal properties are rigorously evaluated. This process has undergone a transformative evolution, driven by the imperative need for more efficient, rapid, and high-throughput screening platforms. Among these, microfluidic systems have emerged as the epitome of efficiency, enabling the screening of drug candidates with unprecedented speed and minimal sample consumption. This review paper explores the cutting-edge landscape of microfluidic-based drug screening platforms, with a specific emphasis on two pioneering approaches: organ-on-a-chip and C. elegans-based chips. Organ-on-a-chip technology harnesses human-derived cells to recreate the physiological functions of human organs, offering an invaluable tool for assessing drug efficacy and toxicity. In parallel, C. elegans-based chips, boasting up to 60% genetic homology with humans and a remarkable affinity for microfluidic systems, have proven to be robust models for drug screening. Our comprehensive review endeavors to provide readers with a profound understanding of the fundamental principles, advantages, and challenges associated with these innovative drug screening platforms. We delve into the latest breakthroughs and practical applications in this burgeoning field, illuminating the pivotal role these platforms play in expediting drug discovery and development. Furthermore, we engage in a forward-looking discussion to delineate the future directions and untapped potential inherent in these transformative technologies. Through this review, we aim to contribute to the collective knowledge base in the realm of drug screening, providing valuable insights to researchers, clinicians, and stakeholders alike. We invite readers to embark on a journey into the realm of microfluidic-based drug screening platforms, fostering a deeper appreciation for their significance and promising avenues yet to be explored.

Funder

National Research Foundation of Korea

Korea Environmental Industry & Technology Institute

Ministry of Environment (MOE) of the Republic of Korea

Publisher

MDPI AG

Subject

Clinical Biochemistry,General Medicine,Analytical Chemistry,Biotechnology,Instrumentation,Biomedical Engineering,Engineering (miscellaneous)

Reference112 articles.

1. Drug Screening and Evaluative Procedures;Irwin;Science,1962

2. Principles of Early Drug Discovery;Hughes;Br. J. Pharmacol.,2011

3. HTS Technologies in Biopharmaceutical Discovery;Wu;Drug Discov. Today,2006

4. Iversen, P.W., Beck, B., Chen, Y.-F., Dere, W., Devanarayan, V., Eastwood, B.J., Farmen, M.W., Iturria, S.J., Montrose, C., and Moore, R.A. (2012). HTS Assay Validation, Assay Guidance Manual.

5. Evaluation of Alternative in Vivo Drug Screening Methodology: A Single Mouse Analysis;Murphy;Cancer Res.,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3